BSE Live
Oct 23, 12:38Prev. Close
842.05
Open Price
842.75
Bid Price (Qty.)
837.25 (274)
Offer Price (Qty.)
837.90 (1)
NSE Live
Oct 23, 12:38Prev. Close
842.00
Open Price
848.00
Bid Price (Qty.)
837.65 (17)
Offer Price (Qty.)
837.85 (66)
Profit & Loss account of Natco Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 4,076.60 | 3,548.90 | 2,340.80 | 1,761.70 | 1,617.70 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 4,076.60 | 3,548.90 | 2,340.80 | 1,761.70 | 1,617.70 | |
Total Operating Revenues | 4,094.50 | 3,568.90 | 2,351.00 | 1,767.80 | 1,653.50 | |
Other Income | 321.30 | 104.70 | 85.50 | 94.60 | 101.10 | |
Total Revenue | 4,415.80 | 3,673.60 | 2,436.50 | 1,862.40 | 1,754.60 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 536.20 | 522.50 | 475.30 | 519.20 | 372.90 | |
Purchase Of Stock-In Trade | 45.50 | 34.80 | 19.80 | 20.90 | 174.00 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | 11.60 | 17.20 | 34.60 | -5.50 | -46.90 | |
Employee Benefit Expenses | 515.30 | 454.90 | 425.70 | 410.10 | 380.00 | |
Finance Costs | 19.60 | 14.50 | 8.60 | 13.30 | 11.30 | |
Depreciation And Amortisation Expenses | 220.00 | 171.90 | 150.90 | 138.40 | 115.20 | |
Other Expenses | 841.60 | 902.50 | 550.90 | 610.10 | 355.90 | |
Total Expenses | 2,189.80 | 2,118.30 | 1,665.80 | 1,706.50 | 1,362.40 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,226.00 | 1,555.30 | 770.70 | 155.90 | 392.20 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 2,226.00 | 1,555.30 | 770.70 | 155.90 | 392.20 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 407.50 | 284.80 | 133.10 | 32.50 | 93.30 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -31.90 | -36.10 | 0.50 | -15.70 | -10.60 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 375.60 | 248.70 | 133.60 | 16.80 | 82.70 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 1,850.40 | 1,306.60 | 637.10 | 139.10 | 309.50 | |
Profit/Loss From Continuing Operations | 1,850.40 | 1,306.60 | 637.10 | 139.10 | 309.50 | |
Profit/Loss For The Period | 1,850.40 | 1,306.60 | 637.10 | 139.10 | 309.50 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 103.31 | 72.79 | 34.90 | 7.63 | 16.99 | |
Diluted EPS (Rs.) | 103.31 | 72.79 | 34.90 | 7.63 | 16.96 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 107.50 | 170.20 | 100.40 | 82.10 | 113.90 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Equity Dividend Rate (%) | 300.00 | 475.00 | 275.00 | 225.00 | 263.00 |
14.10.2025
Natco Pharma shares fall 3.5% as SC agrees to urgently list Roche's plea on Risdiplam launch
10.10.2025
Natco Pharma shares jump 6% after Delhi HC allows firm to sell 'Risdiplam' in India
10.10.2025
09.09.2025
Natco Pharma Standalone June 2025 Net Sales at Rs 1,192.70 crore, down 3.57% Y-o-Y
09.09.2025
Natco Pharma Standalone June 2025 Net Sales at Rs 1,192.70 crore, down 3.57% Y-o-Y
05.06.2025
Natco Pharma Standalone March 2025 Net Sales at Rs 1,157.40 crore, up 19.96% Y-o-Y
03.06.2025
Natco Pharma Consolidated March 2025 Net Sales at Rs 1,221.00 crore, up 14.29% Y-o-Y
28.02.2025
Natco Pharma Consolidated December 2024 Net Sales at Rs 474.80 crore, down 37.41% Y-o-Y